text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 182431-12-5 | Product Number: L0298

Lomitapide


Purity: >98.0%(HPLC)(qNMR)
Synonyms:
  • N-(2,2,2-Trifluoroethyl)-9-[4-[4-[4'-(trifluoromethyl)-[1,1'-biphenyl]-2-ylcarboxamido]piperidin-1-yl]butyl]-9H-fluorene-9-carboxamide
  • AEGR-733
  • BMS-201038
Product Documents:
25MG
167,00 €
1   22  
100MG
448,00 €
1   33  

*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).


Product Number L0298
Purity / Analysis Method >98.0%(HPLC)(qNMR)
Molecular Formula / Molecular Weight C__3__9H__3__7F__6N__3O__2 = 693.73 
Physical State (20 deg.C) Solid
Storage Temperature Refrigerated (0-10°C)
Condition to Avoid Heat Sensitive
Packaging and Container 100MG-Glass Bottle with Plastic Insert (View image),  25MG-Glass Bottle with Plastic Insert (View image)
CAS RN 182431-12-5
Reaxys Registry Number 13754976
PubChem Substance ID 354335361
MDL Number

MFCD16620494

Specifications
Appearance White to Almost white powder to crystal
Purity(HPLC) min. 98.0 area%
Purity(qNMR) min. 98.0 %
NMR confirm to structure
Properties (reference)
Melting Point 142 °C
GHS
Related Laws:
Transport Information:
HS Number 2933399990
Application
Lomitapide: A Microsomal Triglyceride Transfer Protein (MTP) Inhibitor

Lomitapide (AEGR-733 or BMS-201038) is a microsomal triglyceride transfer protein (MTP) inhibitor. MTP is a lipid transfer protein that resides in the endoplasmic reticulum of hepatocytes and intestinal epithelial cells, and is required for the assembly and secretion of apolipoprotein B (apo B)-containing lipoproteins by the liver and by the intestine. Lomitapide directly binds and inhibits MTP, thereby preventing the assembly of apolipoprotein B-containing lipoproteins in hepatocytes and intestinal epithelial cells. This inhibits the synthesis chylomicros of and very low-density lipoprotein (VLDL). The inhibition of the synthesis of VLDL leads to reduced levels of low-density lipoprotein cholesterol (LDC-C) in plasma. In addition, lomitapide mesylate [CAS: 202914-84-9] is used for clinical. (The product is for research purpose only.)

References


PubMed Literature


Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.

The requested SDS is not available.

Please Contact Us for more information.

Specifications
C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The product with the lot number searched for has been discontinued and no related documentation is available.

Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.

A sample C of A for this product is not available at this time.

Analytical Charts
Please enter Lot Number Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.

The requested analytical chart is not available. Sorry for the inconvenience.

The product with the lot number searched for has been discontinued and no related documentation is available.

Other Documents

Session Status
Your session will timeout in 10 minutes. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page. minute. You will be redirected to the HOME page after session timeout. Please click the button to continue session from the same page.

Your session has timed out. You will be redirected to the HOME page.